Testing effectiveness (Phase 2)Looking for participantsNCT07296705
What this trial is testing
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital 25